{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:37:54Z","timestamp":1789141074348,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013109","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000}}],"reference-count":73,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013109.pub2","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T01:39:53Z","timestamp":1613525993000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Aldosterone antagonists for people with chronic kidney disease requiring dialysis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Takeshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Showa University Research Administration Center (SURAC); Showa University; Tokyo Japan"},{"name":"Division of Nephrology, Department of Medicine, School of Medicine; Showa University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine; Showa University Fujigaoka Hospital; Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ota","sequence":"additional","affiliation":[{"name":"Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William MM","family":"Levack","sequence":"additional","affiliation":[{"name":"Rehabilitation Teaching and Research Unit, Department of Medicine; University of Otago; Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Data Science; The Institute of Statistical Mathematics; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0003|cit3","first-page":"100A","article-title":"Spironolactone prevents cardiac hypertrophy in peritoneal dialysis patients without significant adverse effects [abstract no: SA-OR127]","volume":"24","author":"Ito","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013109.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013109.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"Journal of Clinical Hypertension"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0006|cit6","first-page":"36A","article-title":"Spironolactone reduces cardio-and cerebrovascular morbidity and mortality in hemodialysis patients [abstract no: FR-OR025]","volume":"23","author":"Matsumoto","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013109.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD013109.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/ndt\/gft409","article-title":"Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa)","volume":"29","author":"Hammer","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013109.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"i218","DOI":"10.1093\/ndt\/gfy104.FP532","article-title":"The prognostic value of nephro-cardiac biomarkers in hemodialysis patients-the randomized-controlled MiREnDa trial [abstract no: FP532]","volume":"33","author":"Hauser","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0011|cit11","first-page":"899","article-title":"Effect of spironolactone on the left ventricular mass in hemodialysis patients: the MiREnDa study- a randomized controlled trial. [abstract no: SA-PO849]","volume":"28","author":"Wanner","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD013109.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"Journal of Clinical Hypertension"},{"issue":"9","key":"10.1002\/14651858.CD013109.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0014|cit14","first-page":"605A","article-title":"Safety of eplerenone in hemodialysis patients: a randomized controlled trial [abstract no: FR-PO1016]","volume":"25","author":"Walsh","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0015|cit15","first-page":"B9","article-title":"Safety and cardiovascular efficacy of spironolactone (SPL) in dialysis-dependent ESRD (SPin-D): a pilot trial of the NIDDK Hemodialysis Novel Therapies Consortium [abstract no: FR-PO1078]","volume":"28","author":"Charytan","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0017|cit17","unstructured":"Najafabadi MM Taheri S Seyrafian S Alipoor Z Karimi S Poormodhadas A Spironolactone in continuous ambulatory peritoneal dialysis patients, improves cardiac function [abstract no: SU475] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"3","key":"10.1002\/14651858.CD013109.pub2-BIB0018|cit18","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013109.pub2-BIB0019|cit19","first-page":"vi145","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]","volume":"22","author":"Mortazavi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD013109.pub2-BIB0020|cit20","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0021|cit21","unstructured":"Taheri S Mortazavi M Shahidi S Pourmoghadas A Garakyaraghi M Seirafian S Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: S-PO-0370] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 148"},{"issue":"6","key":"10.1002\/14651858.CD013109.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1053\/j.ajkd.2014.01.426","article-title":"Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial","volume":"63","author":"Vazquez-Rangel","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0023|cit23","first-page":"549A","article-title":"Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial [abstract no: FR-PO789]","volume":"23","author":"Vazquez-Rangel","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD013109.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/1744-9987.12219","article-title":"Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients","volume":"19","author":"Yongsiri","year":"2015","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"5","key":"10.1002\/14651858.CD013109.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"A116","DOI":"10.1053\/j.ajkd.2014.01.407","article-title":"Spironolactone for hypokalia in CAPD patients, a randomized, double-blind, placebo controlled trial [abstract no: 390]","volume":"63","author":"Yongsiri","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013109.pub2-BIB0027|cit27","first-page":"ii238","article-title":"Renin angiotensin aldosterone system blockade and left ventricular hypertrophy in maintenance hemodialysis patients [abstract no: FP497]","volume":"27","author":"Zaripova","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0028|cit28","first-page":"45","article-title":"Effects of spironolactone on cardiovascular complications in hemodialysis patients of Taleghani Hospital during the period of 2016-2017: a randomized double-blind controlled clinical trial","volume":"20","author":"Ziaee","year":"2019","journal-title":"Iranian Heart Journal"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013109.pub2-BIB0029|cit29","first-page":"305","article-title":"Effect of spironolactone on vascular stiffness in hemodialysis - a randomized crossover study [abstract no: TH-PO913]","volume":"27","author":"Eklund","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0030|cit30","first-page":"595","article-title":"EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial","volume":"19","author":"Girerd","year":"2018","journal-title":"Trials [Electronic Resource]"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013109.pub2-BIB0031|cit31","first-page":"vi322","article-title":"The influence of spironolactone on plasma level of plasminogen-activator inhibitor type 1 (PAI-1) in anuric hemodialysis patients [abstract no: SaP266]","volume":"22","author":"Essaian","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD013109.pub2-BIB0032|cit32","first-page":"A215","article-title":"Long term spironolactone and cardiac function in chronic uremia [abstract]","volume":"15","author":"Host","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013109.pub2-BIB0033|cit33","first-page":"S137","article-title":"Randomized controlled trial on the antihypertensive effect of spironolactone in addition to salt restriction in peritoneal dialysis patients [abstract]","volume":"30","author":"Koh","year":"2010","journal-title":"Peritoneal Dialysis International"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0034|cit34","unstructured":"Charytan D L-arginine and spironolactone trial in dialysis-dependent ESRD (LAST-D) www.clinicaltrials.gov\/ct2\/show\/NCT01855334"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD013109.pub2-BIB0035|cit35","first-page":"709A","article-title":"Effects of combined b-blocker and anti-aldosterone antagonist treatment for cardiovascular prevention in patients receiving maintenance hemodialysis [abstract no: SU-PO573]","volume":"18","author":"Nakao","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0036|cit36","unstructured":"Narsipur SS Spironolactone safety in dialysis patients www.clinicaltrials.gov\/ct2\/show\/NCT00328809"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.23876\/j.krcp.18.0115","article-title":"Efficacy of triple diuretic treatment in continuous ambulatory peritoneal dialysis patients: a randomized controlled trial","volume":"38","author":"Witoon","year":"2019","journal-title":"Kidney Research & Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD013109.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1590\/2175-8239-jbn-2019-0009","article-title":"Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study","volume":"41","author":"Gueiros","year":"2019","journal-title":"Jornal Brasileiro de Nefrologia"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0039|cit39","unstructured":"Liu H Residual renal function preservation in peritoneal dialysis patients www.clinicaltrials.gov\/ct2\/show\/NCT02190318"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0040|cit40","unstructured":"Ruengorn C Effect of add-on spironolactone to losartan versus losartan alone on peritoneal membrane among peritoneal dialysis patients (ESCAPE-PD) www.clinicaltrials.gov\/show\/nct03953950"},{"issue":"19","key":"10.1002\/14651858.CD013109.pub2-BIB0041|cit41","first-page":"2947","article-title":"Effect of spironolactone on cardiac function, dialysis adequacy and complications in hemodialysis","volume":"33","year":"2017","journal-title":"Journal of Modern Medicine & Health"},{"issue":"8","key":"10.1002\/14651858.CD013109.pub2-BIB0042|cit42","first-page":"1303","article-title":"Effects of spironolacone on cardiac and residual renal function in patients with peritoneal dialysis","volume":"16","author":"Wang","year":"2018","journal-title":"Chinese Journal of General Practice"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0043|cit43","unstructured":"Walsh M Devereaux PJ Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE) www.clinicaltrials.gov\/ct2\/show\/NCT03020303"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0044|cit44","unstructured":"Rossignol P ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST) www.clinicaltrials.gov\/ct2\/show\/NCT01848639"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0045|cit45","unstructured":"Michea LF Cardiovascular protective effect of spironolactone in hemodialysis www.clinicaltrials.gov\/ct2\/show\/NCT00277693"},{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004.pub3","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney International"},{"issue":"5 Suppl 3","key":"10.1002\/14651858.CD013109.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"7650","key":"10.1002\/14651858.CD013109.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013109.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013109.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney International"},{"issue":"7414","key":"10.1002\/14651858.CD013109.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0055|cit55","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD013109.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report.[Erratum appears in Kidney Int. 2011 Nov;80(9):1000], [Erratum appears in Kidney Int. 2011 Nov 1;80(9):1000; PMID: 30036909]","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0057|cit57","first-page":"1925243","article-title":"Aldosterone antagonists reduce the risk of cardiovascular mortality in dialysis patients: a meta-analysis","author":"Li","year":"2019","journal-title":"Evidence-Based Complementary & Alternative Medicine: eCAM"},{"issue":"9981","key":"10.1002\/14651858.CD013109.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD013109.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD013109.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.[Erratum in: N Engl J Med. 2003 May 29;348(22):2271]","volume":"348","author":"Pitt","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013109.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis","volume":"68","author":"Quach","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD013109.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0272-6386(95)90492-1","article-title":"Hypertension in the hemodialysis population: a survey of 649 patients","volume":"26","author":"Salem","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"9 Pt 1","key":"10.1002\/14651858.CD013109.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"American Journal of Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD013109.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic haemodialysis patients","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0065|cit65","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0066|cit66","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0067|cit67","unstructured":"The SONG Handbook Version 1.0 www.songinitiative.org\/reports-and-publications\/"},{"issue":"3","key":"10.1002\/14651858.CD013109.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013109.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000100106","article-title":"Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis","volume":"27","author":"Steigerwalt","year":"2007","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0070|cit70","unstructured":"2017 Annual Data Report. Chapter 8: Cardiovascular Disease in Patients with ESRD www.usrds.org\/media\/1687\/v2_c08_cvd_17.pdf"},{"key":"10.1002\/14651858.CD013109.pub2-BIB0071|cit71","unstructured":"2017 Annual Data Report. Chapter 5: Mortality www.usrds.org\/media\/1681\/v2_c05_mortality_17.pdf"},{"issue":"16","key":"10.1002\/14651858.CD013109.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD013109.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013109","article-title":"Aldosterone antagonists for people with chronic kidney disease requiring dialysis","author":"Hasegawa","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T09:18:36Z","timestamp":1625131116000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013109.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013109.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}